CNBC
Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
Thursday, November 19, 2026
Novartis raised peak sales forecasts for multiple drugs across multiple sclerosis, leukemia, and cholesterol treatments to $18 billion combined, citing strong demand. The company did not specify which drugs received upgraded forecasts or by how much each was increased. The announcement came as part of the company's effort to demonstrate sustained revenue growth.
Original reporting:
